Skip to main content

Peer Review reports

From: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Original Submission
5 Apr 2019 Submitted Original manuscript
20 May 2019 Reviewed Reviewer Report - Ursa Brown-Glaberman
19 Jun 2019 Reviewed Reviewer Report - Satoru Seo
16 Jul 2019 Reviewed Reviewer Report - Mairead Geraldine McNamara
1 Aug 2019 Author responded Author comments - Lukas Perkhofer
Resubmission - Version 2
1 Aug 2019 Submitted Manuscript version 2
20 Aug 2019 Author responded Author comments - Lukas Perkhofer
Resubmission - Version 3
20 Aug 2019 Submitted Manuscript version 3
2 Sep 2019 Author responded Author comments - Lukas Perkhofer
Resubmission - Version 4
2 Sep 2019 Submitted Manuscript version 4
Publishing
9 Sep 2019 Editorially accepted
23 Oct 2019 Article published 10.1186/s12885-019-6142-y

You can find further information about peer review here.

Back to article page